top of page
Publications
Communicating Evidence
Year | Title | Authors | Journal / Meeting |
|---|---|---|---|
2025 | Patient, Care Partner, and Provider Voice in Treatment Decision-Making for Non-Small Cell Lung Cancer | Dwyer Orr L, Vanderpoel J, Vadagam P, Indravadan Patel M, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE | Patient Education and Counseling |
2025 | A validation study of the Clinician’s Tardive Inventory (CTI) | Trosch RM, Shillington AC, Comella CL, Caroff SN, Ondo WG, LaChappelle BJ, Harshaw Q, Hauser RA, Correll CU, Friedman JH | Parkinsonism and Related Disorders |
2025 | A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Areata (encore) | Del Rosso J, Pariser D, Bhatia N, Harshaw Q, Deering KL, Barghout V, Ferro T | Academy of Managed Care Pharmacy (AMCP) 2025 |
2025 | Patient preference among Janus kinase inhibitors for the treatment of alopecia areata (encore) | Mesinkovska N, Harshaw Q, Deering KL, Barghout V, Ferro T | Academy of Managed Care Pharmacy (AMCP) 2025 |
2025 | A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Areata (ePoster) | Del Rosso J, Pariser D, Bhatia N, Harshaw Q, Deering KL, Barghout V, Ferro T | American Academy of Dermatology (AAD) Annual Meeting 2025 |
2025 | Patient preference among Janus kinase inhibitors for the treatment of alopecia areata (ePoster and oral presentation) | Mesinkovska N, Harshaw Q, Deering KL, Barghout V, Ferro T | American Academy of Dermatology (AAD) Annual Meeting 2025 |
2024 | Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study | Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown J, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP | ASCO Genitourinary Cancers Symposium 2024 |
2024 | Measurement of clinical documentation burden associated with tracking immunology-related products requiring Intravenous (IV) induction and Subcutaneous (SQ) maintenance | Lajthia E, Deering KL, Patel AA, Shah S | Advances in Inflammatory Bowel Disease (AIBD) |
2024 | Impact of comprehensive pharmacy services on inflammatory bowel disease patient care at Ochsner Health | Lajthia E, Babin S, Deering KL, Patel AA, Shah S | Advances in Inflammatory Bowel Disease (AIBD) |
2024 | Barriers to Inflammatory Bowel Disease Care in a Majority Hispanic Population: A Patient Survey | Odafal FD, Patel AA, Deering KL, Arias CF, Yung M, Shillington AC | Advances in Inflammatory Bowel Disease (AIBD) |
2024 | Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study | Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown J, Dave V, Downey C, Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP | Clinical Genitourinary Cancer |
2024 | A Discrete Choice Experiment to Assess Clinician Preferences for the Treatment of Alopecia Areata | Del Rosso J, Pariser D, Bhatia N, Harshaw Q, Deering KL, Barghout V, Ferro T | Fall Clinical Dermatology Conference |
2024 | Patient Preferences For The Treatment of Alopecia Areata | Mesinkovska N, Harshaw Q, Deering KL, Barghout V, Ferro T | Fall Clinical Dermatology Conference |
2024 | Patient and care partner perspectives and preferences related to myasthenia gravis treatment: A qualitative study | Yung M, Narayanaswami P, Pesa J, Choudhry Z, Jackson L, Deering KL, Sebaaly J, Richardson J, Feldman J, Peters W, Taylor M, Foss A, West B, Shea L, Geonnotti G, Govindarajan R | Health Science Reports |
2024 | The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia | Trosch RM, Comella CL, Caroff SN, Ondo WG, Shillington AC, LaChappelle BJ, Hauser RA, Correll CU, Friedman JH | Journal of Clinical Psychiatry |
2024 | Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program | Yang E, Kruger E, Yin D, Mace K, Tierney M, Liao N, Cibelli E, Drozd D, Ross N, Deering KL, Herout P, Harshaw Q, Shillington A, Thomas N, Marsden D, Kritzer A, Vockley J | Molecular Genetics and Metabolism |
2024 | Patient, Care Partner, and Physician Voices in Treatment Decision-Making for Multiple Myeloma | Dwyer Orr L, Lin D, Wu B, LeBlanc T, FAiman B, Ahlstrom J, Yung M, Deering KL, Kulbokas V, Feldman JL, Kline E, Biran N | Patient Preference and Adherence |
2023 | Real-world Outcomes and Tolerability of Eslicarbazepine Acetate as an Add-on or Switch from Levetiracetam Monotherapy | Grinnell TA, Cantu D, Sachdeva PL, Deering KL, LaChappelle B, Sebaaly J, Harshaw Q | 2023 Annual American Epilepsy Society (AES) Meeting |
2023 | Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States | Larsen NJ, Deering KL, Weiss B, Loustau P, Culler MD, Allas S, Mitchell DM | AMCP NEXUS 2023 |
2023 | Baseline characteristics from a retrospective, observational, US-based, multicenter, real-world study of avelumab first-line maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) (PATRIOT-II) | Grivas P, Barata P, Moon H, Hutson T, Gupta S, Sternberg CN, Dave V, Downey C, Shillington AC, Devgan G, Kirker M, Thakkar S, Katzenstein HM, Bhanegaonkar A, Liu FX, Brown J, Sonpavde GP | ASCO Genitourinary Cancers Symposium 2023 |
2023 | Real-World Major Clinical Events and Healthcare Resource Use Among Patients with Long-Chain Fatty Acid Oxidation Disorders in the United States | Yang E, Kruger E, Deering KL, Yin D, Mace K, Liao NS, Tierney M, Cibelli E, Drozd D, Ross N, Herout P, Shillington A, Thomas N, Marsden D, Kritzer A, Vockley J | American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting 2023 |
2023 | Perspectives on symptoms and treatments for Myasthenia Gravis: a real-world voice analysis of open social media | Narayanaswami P, Pesa J, Chaudhry Z, Heerlein K, Herout P, Richardson J, Feldman J, Deering K, Yung M, Kulbokas V, Boyce P, Shillington A | Congress of the European Academy of Neurology (EAN) 2023 |
2023 | Variations in Clinical Practice Patterns for Hypoparathyroidism | Deering K, Larsen N, Loustau P, Weiss B, Culler M, Allas S, Weiss B, Mitchell D | ENDO 2023 |
2023 | Racial Differences in Determinants of Treatment Decision Making
Among Patients With Multiple Myeloma | Dwyer LL, Lin D, Wu B, Biran N, Faiman B, Ahlstrom JM, Herout P, Deering KL, Yung M, Kulbokas V, Feldman JL, Kilne ED, LeBlanc TW | European Hematology Association (EHA) Congress 2023 |
2023 | Shared Decision Making in Multiple Myeloma: Do Patients, Caregivers,
and Physicians Share the Same Goals and Preferences? | Dwyer LL, Lin D, Wu B, LeBlanc TW, Faiman B, Ahlstrom JM, Herout P, Deering KL, Yung M, Kulbokas V, Feldman JL, Kilne ED, Biran N | European Hematology Association (EHA) Congress 2023 |
2023 | Reduced heart failure-related healthcare costs with Furoscix versus in-hospital intravenous diuresis in heart failure patients: the FREEDOM-HF study | Bensimhon D, Weintraub WS, Peacock WF, Alexy T, McLean D, Deering KL, Millar SJ, Goodwin MM, Mohr JF | Future Cardiology |
2023 | Racial and ethnic disparities in patients with inflammatory bowel disease: an online survey | Shah S, Shillington AC, Kabagambe EK, Deering KL, Babin S, Capelouto J, Pulliam C, Patel A, LaChappelle B, Liu J | Inflammatory Bowel Diseases |
2023 | Patient and Care Partner Preferences Related to Treatments for Myasthenia Gravis | Narayanaswami P, Govindarajan R, Foss A, Pesa J, Jackson L, Geonnotti G, Shea L, Choudhry Z, Deering KL, Yung M, Sebaaly J, Wesley Peters, Melina Taylor | National Organization for Rare Disorders (NORD) Breakthrough Summit 2023 |
2023 | Real-World Major Clinical Events and Healthcare Resource Use Among Patients with Long-Chain Fatty Acid Oxidation Disorders in the United States (Encoure Presentation) | Yang E, Kruger E, Deering KL, Yin D, Mace K, Liao NS, Tierney M, Cibelli E, Drozd D, Ross N, Herout P, Shillington A, Thomas N, Marsden D, Kritzer A, Vockley J | Southeastern Regional Genetics Group (SERGG) annual meeting 2023 |
2022 | HIV-associated wasting prevalence in the era of modern antiretroviral therapy: a claims database study (2012-2018) | Siddiqui J, Samuel SK, Hayward B, Wirka K, Deering K, Harshaw Q, Phillips A, Harbour M | AIDS |
2022 | PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States | Grivas P, Barata PC, Moon H, Hutson TE, Gupta S, Sternberg CN, Pickard AS, Dave V, Han N, Shillington AC, Devgan G, Kim R, Thakkar S, Katzenstein H, Bhanegaonkar A, Liu F, Sonpavde GP | ASCO Genitourinary Cancers Symposium 2022 |
2022 | Real-world clinical outcomes of first-line ibrutinib or chemoimmunotherapy in patients with chronic lymphocytic leukemia by risk status | Huang Q, Deering KL, Harshaw Q, Leslie LA | Advances in Therapy |
2022 | Budget Impact and Cost-Effectiveness of Intravenous Meloxicam to Treat Moderate-Severe Postoperative Pain | Carter JA, Black LK, Deering KL, Jahr JS | Advances in Therapy |
2022 | Attitudes and Adherence to Inflammatory Bowel Disease (IBD) Medications in a Racially and Ethnically Diverse Population | Shah SB, Kabagambe EK, Shillington AC, Patel AA, Capelouto JA, Deering KL, Babin S, LaChappelle B, Liu JJ | American College of Gastroenterology (ACG) 2022 |
2022 | Barriers to Inflammatory Bowel Disease (IBD) Care in a Racially and Ethnically Diverse Population: Patient Survey and Chart Review Study | Shah SB, Kabagambe EK, Shillington AC, Patel AA, Capelouto JA, Deering KL, Babin S, LaChappelle B, Liu JJ | American College of Gastroenterology (ACG) 2022 |
2022 | Inflammatory Bowel Disease Population Analyzer Tool for Health systems (IBD PATH): A Case Study Risk Stratifying IBD Patients for Clinical Outcomes | Kabagambe EK, Deering KL, Patel AA, Capelouto JA, Babin S, Shah SB | American College of Gastroenterology (ACG) 2022 |
2022 | Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy | Morgans A, Grewal S, Hepp Z, Fuldeore R, Odak S, Macahilig C, Shillington A, Sonpavde G | Clinical Genitourinary Cancer |
2022 | Clinical and Patient-Reported Outcomes of Advanced Urothelial Carcinoma Following Discontinuation of PD-1/L1 Inhibitor Therapy | Morgans AK, Grewal S, Hepp Z, Fuldeore R, Odak S, Macahilig C, Shillington AC, Sonpavde G | Clinical Genitourinary Cancer |
2022 | Major Clinical Manifestations and Events Among Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) in the United States: Real-world Results from LC-FAOD Odyssey | Yang E, Kruger E, Deering KL, Stubbe C, Mace K, Tierney M, Cibelli E, Drozd D, Ross N, Herout P, Shillington A, Thomas N, Marsden D, Kritzer A | ISPOR Annual Meeting |
2022 | First and Second Line Treatment Patterns in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Chart Review Study in Three Countries | Gogate A, Shillington AC, Dave V, Singh P | ISPOR Europe 2022 |
2022 | Prospective Evaluation of Exacerbations Associated with Suboptimal Peak Inspiratory Flow Among Stable Outpatients with COPD | Mahler DA, Niu X, Deering KL, Dembek C | International Journal of Chronic Obstructive Pulmonary Disease |
2022 | The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy | Siddiqui J, Samuel SK, Hayward B, Wirka KA, Deering KL, Harshaw Q, Phillips A, Harbour M | Journal of Managed Care + Specialty Pharmacy |
2022 | Reliability of the Clinician’s Tardive Inventory (CTI) | Trosch RM, Comella CL, Caroff SN, Ondo WG, Shillington AC, LaChappelle BJ, Hauser RA, Correll CU, Friedman JH | Neuroscience Education Institute (NEI) Congress 2022 |
2022 | Health-related quality of life and treatment satisfaction in Chronic Lymphocytic Leukemia (CLL) patients on ibrutinib compared to other CLL treatments in a real-world US cross sectional study | Deering KL, Sundaram M, Harshaw Q, Trudeau J, Barrientos JC | PLoS ONE |
2021 | Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States | Deering K, Loustau P, Culler M, Allas S, Weiss B, Astolfi D, Mitchell D | AMCP NEXUS 2021 |
2021 | Treatment patterns among patients with advanced urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy | Morgans AK, Grewal S, Hepp Z, Fuldeore R, Odak S, Macahilig C, Shillington AC, Sonpavde GP | ASCO Genitourinary Cancers Symposium 2021 |
2021 | Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis | Deering K, Loustau P, Culler M, Allas S, Weiss B, Astolfi D, Mitchell D | American Society for Bone & Mineral Research (ASBMR) 2021 |
2021 | Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery-Based Criteria | Sharma D, Deering K, Loustau P, Culler M, Allas S, Weiss B, Mitchell D, Astolfi D, Mannstadt M | ENDO 2021 |
2021 | Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis-Based Criteria | Sharma D, Deering K, Loustau P, Culler M, Allas S, Weiss B, Mitchell D, Astolfi D, Mannstadt M | ENDO 2021 |
2021 | Assessment of clinical burden and practice patterns in patients with chronic hypoparathyroidism in the united states (us): a claims data analysis using surgery-based criteria | Sharma D, Deering K, Loustau P, Culler M, Allas S, Weiss B, Mitchell D, Astolfi D, Mannstadt M | European Congress of Endocrinology 2021 |
2021 | Assessment of clinical burden and practice patterns in patients with chronic hypoparathyroidism in the united states (us): a claims data analysis using diagnosis-based criteria | Sharma D, Deering K, Loustau P, Culler M, Allas S, Weiss B, Mitchell D, Astolfi D, Mannstadt M | European Congress of Endocrinology 2021 |
2021 | Methods to Identify Patients with Chronic Hypoparathyroidism in the United States (US) Using Claims Data | Sharma D, Deering K, Loustau P, Culler M, Allas S, Weiss B, Mitchell D, Astolfi D, Mannstadt M | ISPOR Annual Meeting |
2021 | Impact of Treatment and Patient Attributes on Oncologists Decision-Making in First-line Chronic Lymphocytic Leukemia (CLL) in the United States (US) | Sharma D, Deering K, Sundaram M, Daly K, Huang Q | ISPOR Annual Meeting |
2020 | Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Satus: Results from a US Retrospective Chart Review Study | Huang Q, Deering KL, Harshaw Q, Bhagnani T, Leslie LA | 2020 American Society of Hematology (ASH) Annual Meeting |
2020 | Heart Failure Related Costs and Health Care Resource Utilization Following an Emergency Department (ED) Visit for Worsening Heart Failure: A Claims Data Analysis | Goodwin MM, Sharma D, Deering KL, Mohr J | 2020 Heart Failure Society of America (HFSA) Annual Meeting |
2020 | Health-related quality of life and treatment satisfaction in Chronic lymphocytic Leukemia (CLL) patients on ibrutinib compared to a reference group on other CLL treatments in a real-world US cross sectional study | Barrientos JC, Sundaram M, Deering KL, Sharma D, Harshaw Q, Trudeau J | 2020 NCCN Annual Conference |
2020 | Cost of Home vs Clinic Administration of Paclitaxel in Metastatic Breast Cancer | Sharma D, Wojtynek J, Fox KM, Cooper C, Dokubo I | American Journal of Managed Care |
2020 | Efficacy of non-opioid analgesics to control postoperative pain: a network metaanalysis | Carter JA, Black LK, Sharma D, Bhagnani T, Jahr JS | BMC Anesthesiology |
2020 | Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma | Jang S, Poretta T, Bhagnani T, Harshaw Q, Burke M, Rao S | Dermatology and Therapy |
2020 | Treatment and Outcomes in Recurrent Metastatic Squamous CELL Carcinoma of the Head and Neck (R/M SCCHN): A Chart Review Study in France, Germany and the United Kingdom (UK) | Singh P, Contente M, Shillington A, Dave V, Kiff C, Cotte FE, Macahilig C. | ISPOR 2020 |
2020 | Development of a patient decision aid for treatment resistant depression | Shillington AC, Langenecker SA, Shelton RC, Foxworth P, Allen L, Rhodes M, Pesa J, Williamson D, Holmes-Rovner M | Journal of Affective Disorders |
2020 | Health-related quality of life (QoL) in patients with advanced melanoma receiving immunotherapies in real-world clinical practice settings | Joseph RW, Liu FX, Shillington AC, Macahilig CP, Diede SJ, Dave V, Harshaw Q, Saretsky TL, Pickard AS | Quality of Life Research |
2019 | Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world | Joseph RW, Shillington AC, Lee T, Macahilig C, Diede SJ, Dave V, Harshaw Q, Taymor E, Liu FX | 2019 ASCO Annual Meeting |
2019 | Development of a Decision Aid in Support of Shared Decision Making for Treatment-resistant Depression | Shelton R, Langenecker S, Foxworth P, Allen L, Rhodes M, Pesa J, Williamson D, Shillington AC, Holmes-Rovner M | 2019 Annual Psych Congress |
2019 | A Cross-Sectional Real-World Evaluation of the Health-Related Quality of Life Burden in Patients with Chronic Lymphocytic Leukemia | Murali Sundaram M, Deering KL, Trudeau J, Harshaw | 2019 SOHO Annual Meeting |
2019 | Network meta-analysis to evaluate intravenous meloxicam versus other intravenous non-opioid medications for moderate-severe postoperative pain | Carter JA, Bhagnani T, Deering KL, Black LK, Jahr JS | 44th Annual Anesthesiology and Acute Pain Meeting (ASRA) 2019 |
2019 | Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab vs. ipilimumab plus nivolumab in US academic centers | Joseph RW, Shillington AC, Lee T, Macahilig C, Diede SJ, Dave V, Harshaw Q, Taymor E, Liu FX | Journal of Medical Economics |
2018 | Factors predicting the use of immunotherapy for patients with advanced melanoma | Joseph RW, Shillington A, Macahilig C, Diede SJ, Dave V, Harshaw Q, Liu FX | 2018 ASCO Annual Meeting |
2018 | Treatment patterns and healthcare resource utilization in patients with relapsed/refactory large b-cell lymphoma (R/R LBCL) in the United States | Lin VW, Cheng P, Shillington AC, Macahilig CP, Purdum AG | 2018 Pan Pacific Lymphoma Conference |
2018 | Meta-analysis of caregiver-directed psychosocial interventions for schizophrenia | Ashcroft K, Kim E, Elefant E, Benson C, Carter JA | Community Mental Health Journal |
2018 | Changing patients' treatment preferences and values with a decision aid for type 2 diabetes mellitus: results from the treatment arm of a randomized controlled trial | Bailey RA, Shillington AC, Harshaw Q, Funnell MM, VanWingen J, Col N | Diabetes Therapy |
2018 | Patient versus neurologist preferences: A discrete choice experiment for antiepileptic drug therapies | Ettinger AB, Carter JA, Rajagopalan K | Epilepsy and Behavior |
2018 | Factors associated with immunotherapy selection in patients with advanced melanoma | Joseph RW, Shillington AC, Macahilig C, Diede SJ, Dave V, Harshaw Q, Liu FX | Immunotherapy |
2017 | Employing Bayesian-calibrated microsimulation to assess the cost-effectiveness of long acting injectable buprenorphine versus sublingual buprenorphine to treat opioid use disorder | Carter JA, Dammerman R, Frost M, Tiberg F | AMCP Annual Meeting |
2017 | Economic analysis of buprenorphine subdermal implant versus standards of care for primarily treatment-naïve primarily heroin-addicted patients with opioid use disorder | Carter JA, Dammerman R, Frost M | AMCP Annual Meeting |
2017 | Cost-effectiveness of long-acting injectable buprenorphine versus sublingual buprenorphine to treat opioid use disorder in Sweden and the United Kingdom | Carter JA, Dammerman R, Tiberg F, Jensen R | AMCP Annual Meeting |
2017 | Determining the Economic Impact of Medication Non-Adherence in Persons Treated with Depot-Injectable or Sublingual Buprenorphine for Opioid Use Disorder | Carter JA, Frost M, Sanjurjo V | AMCP Nexus Annual Meeting |
2017 | Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation | Sharma G, Mahler D, Mayorga V, Deering KL, Harshaw Q, Ganapathy V | Chronic Obstructive Pulmonary Diseases |
2017 | Flexible-dose depot buprenorphine injection for opioid substitution treatment in heroin-addicted adults: A Swedish pharmacoeconomic perspective | Jensen R, Carter JA, Tiberg F, Sanjurjo V | ISPOR 20th Annual European Congress |
2017 | Substitution therapy with flexible-dose depot buprenorphine injection to treat opioid use disorder in the United Kingdom: A pharmacoeconomic assessment | Tiberg F, Carter JA, Jensen R, Sanjurjo V | ISPOR 20th Annual European Congress |
2017 | Treatment and outcomes in recurrent/metastatic squamous cell carcinoma of the head and neck: a chart review study in France | Cotte F , Shaw JW , Juarez Garcia A , Harshaw Q , Macahilig C , Shillington AC | ISPOR 22nd Annual International Meeting |
2017 | Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder | Carter JA, Dammerman R, Frost M | Journal of Medical Economics |
2017 | Treatment and Outcomes in Glioblastoma Multiforme: A multi-country chart review study | Shillington A, Macahilig C, Shaw J, Dastani H | Neuro-Oncology |
2016 | Assessing the health-economic implications of buprenorphine subdermal implants for the treatment of opioid dependence in clinically-stable adults | Carter JA, Dammerman R, Frost M | 27th Annual AAAP Conference |
2016 | Caregiver-directed psychosocial interventions in schizophrenia: A systematic review and meta-analysis | Mancevski B, Ashcroft K, Carter J, Kim E | 29th Annual US Psychiatric and Mental Health Congress |
2016 | Comparing anti-epileptic drug preferences between neurologists and patients: Results from a national survey and discrete choice experiment | Velez FF, Carter JA, Ettinger AB | 68th American Academy of Neurology Annual Meeting |
2016 | Application of a national survey and discrete choice experiment to explore drivers of patient preferences for anti-epileptic drugs | Ettinger AB, Velez FF, Carter JA | 70th Annual American Epilepsy Society Meeting |
2016 | Subdermal buprenorphine implants improve societal outcomes and patient morbidity and mortality relative to sublingual buprenorphine: Results of a Markov model | Frost M, Dammerman R, Carter JA, Chen M, Ling W | AMCP Annual Meeting |
2016 | Budgetary impact of implantable buprenorphine versus sublingual buprenorphine, injectable naltrexone, or methadone to treat opioid dependence in clinically stable adults | Carter JA, Dammerman R, Frost M | APhA 2016 Annual Meeting and Expo |
2016 | Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict | Bailey RA, Pfeifer M, Shillington AC, Harshaw Q, Funnell MM, Vanwingen J, Col N | BMC Health Services Research |
2016 | Subdermal buprenorphine implants improve societal outcomes and patient morbidity and mortality relative to sublingual buprenorphine: Results of a Markov model | Frost M, Dammerman R, Carter JA, Chen M, Ling W | CSTE Annual Meeting |
2016 | Modeling the effectiveness of subdermally implanted buprenorphine, injectable naltrexone and sublingual buprenorphine for clinically stable adults with opioid dependence | Frost M, Dammerman R, Carter JA | ISAM and CSAM-SMCA 27th Annual Scientific Conference |
2016 | Two-Year Advanced Melanoma Survival in Treatment Naïve Subjects Initiated With First-Line Ipilimumab 3mg / kg Therapy : Evidence From a US Multisite Retrospective Chart Review | Rao S, Macahili CP, Wolthoff P, Harshaw Q, Shillington A | National Comprehensive Cancer Network 21st Annual Conference |
2016 | The impact of patient support programs on adherence, clinical,\humanistic, and economic patient outcomes: a targeted systematic review | Ganguli, Arijit, Clewell, Jerry, Shillington, Alicia C | Patient Preference and Adherence |
2016 | Knowledge of binge eating disorder: A cross-sectional survey of physicians in the United States | Supina, Dylan, Herman, Barry K., Frye, Carla B., Shillington, Alicia C. | Postgraduate Medicine |
2015 | A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment | Trosch RM, Shillington AC, English ML, Marchese D | Journal of Managed Care & Specialty Pharmacy |
2015 | The National Breakthrough Pain Study: Prevalence, characteristics, and associations with health outcomes | Narayana A, Katz N, Shillington AC, Stephenson JJ, Harshaw Q, Frye CB, Portenoy RK | Pain |
2015 | Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone | Shillington AC, Col N, Bailey RA, Jewell MA | Patient Preference and Adherence |
2015 | Improving access to shared decision-making for Hispanics/Latinos with inadequately controlled Type 2 diabetes mellitus | Davidson J, Allende-Vigo M, Aguilar R, Bailey R, Martin S, Shillington AC | Patient Preference and Adherence |
2014 | The Dysport Economic Evaluation Program (DEEP): A Cost Analysis of Cervical Dystonia (CD) Treatment Switch from onabotulinumtoxinA (Botox [ONA]) to abobotulinumtoxinA (Dysport [ABO]) | Trosch RM, English ML, Shillington AC, Marchese D | 18th International Congress of Parkinson's Disease and Movement Disorders |
2014 | Improving Access to Shared Decision Making for Latin Americans with Inadequately Controlled Type 2 Diabetes Mellitus | Davidson J, Allende-Vigo M, Aguilar R, Bailey R, Martin S, Shillington AC | AACE 23rd Annual Scientific and Clinical Congress |
2014 | Shared Decision-Making and a Patient Decision Aid for Inadequately Controlled Type 2 Diabetes Mellitus | Shillington AC, Col N, Bailey RA, Martin S | American Association of Diabetes Educators Annual Meeting |
2014 | The AbobotulinumtoxinA Economic Evaluation Program (DEEP): A Cost Analysis Of Cervical Dystonia (CD) Treatment Switch From OnabotulinumtoxinA (Botulinum Toxin A [ONA]) To AbobotulinumtoxinA ([ABO]) | Trosch RM, English ML, Shillington AC, Marchese D | Movement Disorders |
2014 | Cultural Adaptation of a Patient Decision Aid for Inadequately Controlled Type 2 Diabetes Mellitus in Latinos | Aguilar R, Davidson J, Allende-Vigo M, Bailey R, Shillington A | National Hispanic Medical Association Meeting 18th Annual Conference |
2014 | Systematic review of measures of personal recovery used in schizophrenia | Shillington A, Benson C, Frye C | Value in Health |
2013 | Prevalence of Axial SpA in US Rheumatology Practices: Assessment of ASAS Criteria vs Rheumatology Expert Clinical Diagnosis | Strand V, Rao SA, Shillington AC, Cifaldi MA, McGuire M, Ruderman EM | Arthritis Care Res |
2013 | Costs Associated with Intravenous Patient Controlled Analgesia (IV PCA) in US Hospitals | Schechter LN, Harshaw Q, Ernst FR, Krukas MR, Shillington AC | ISPOR 18th Annual International Meeting |
2013 | Middle-of-the-night hypnotic use in a large national health plan | Roth T, Berglund P, Shahly V, Shillington AC, Stephenson JJ, Kessler RC | J Clin Sleep Med |
2013 | Composite International Diagnostic Interview Screening Scales for DSM-IV Anxiety and Mood Disorders | Kessler RC, Calabrese JR, Farley PA, Gruber MJ, Jewell MA, Katon W, Keck PE, Nierenberg AA, Sampson NA, Shear MK, Shillington AS, Stein MB, Thase ME, Wittchen HU | Psychol Med |
2012 | Costs Associated with Breakthrough Pain in Cancer Patients | Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, White RE, Portenoy R | American Academy of Pain Management |
2012 | Effect of Breakthrough Pain on Functional Status, Pain Interference, and Disability in Cancer Patients: Findings from the National Breakthrough Pain Survey | Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, Portenoy R | American Society of Clinical Oncology Annual Meeting |
2012 | Prevalence Estimates of Axial Spondyloarthritis Among Patients in German Rheumatology Practices | Rao S, Cifaldi M, Joshi AD, Shillington A, McGuire M, Wittig B, Rudwaleit M | Ann Rheum Dis |
2012 | Prevalence Estimate and Gender Distribution of Axial Spondyloarthritis Among Patients in US Rheumatology Practices | Rao S, Shillington AC, Strand V, McGuire M, Cifaldi MA | Annual European Congress of Rheumatology |
2012 | The Associations of Insomnia with Costly Workplace Accidents and Errors: Results from the America Insomnia Survey | Shahly V, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shillington AC, Stephenson JJ, Walsh JK, Kessler RC | Arch Gen Psychiatry |
2012 | Current Practices in the Management of Chronic Myeloid Leukemia | Kantarjian HK, Larson, RA, Cortes JE, Deering KL, Mauro MJ | Clin Lymphoma Myeloma Leuk |
2012 | Validation of a Tool to Assess Medication Treatment Satisfaction in Patients with Type 2 Diabetes: the Diabetes Medication System Rating Questionnaire (DMSRQ) | Peyrot M, Harshaw Q, Shillington AC, Xu Y, Rubin RR | Diabet Med |
2012 | Costs Associated With Breakthrough Pain in Cancer Patients: Findings From the National Breakthrough Pain Survey | Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, Portenoy R | ISPOR 18th Annual International Meeting |
2012 | Bleeding-associated Outcomes with Preoperative Clopidogrel Use in On- and Off-pump Coronary Artery Bypass | Berger, JS, Herout PM, Harshaw Q, Steinhubl SR, Frye CB, Becker RC | J Thromb Thrombolysis |
2012 | The National Breakthrough Pain Survey: Multivariate Predictors of Functional Status, Pain Interference, and Disability | Narayana A, Katz N, Shillington A, Stephenson J, Portenoy R | PAINWeek |
2012 | The Cost Associated with Breakthrough Pain: Findings from the National Breakthrough Pain Survey | Narayana A, Katz N, Shillington A, Stephenson J, Portenoy R | PAINWeek |
2012 | Breakthrough Pain and Its Association with Functional Status, Pain Interference, and Disability in Cancer Patients: Findings from the National Breakthrough Pain Study | Narayana A, Katz N, Shillington AC, Stephenson JJ, Frye C, White RE, Portenoy R | PAINWeek |
2012 | Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey | Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JK | Sleep |
2012 | Insomnia, Cormorbidity, and Risk of Injury Among Insured Americans: Results from the America Insomnia Survey | Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JK | Sleep Health and Safety |
2012 | The Associations of Insomnia with Costly Workplace Accidents and Errors: Results from the American Insomnia Survey | Shahly V, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shillington AC, Stephenson JJ, Walsh JK, Kessler RC | Sleep Health and Safety |
2011 | Implementation of a Web-Based Patient-Reported Outcomes Research Program | Costello K, Foley J, Miller D, Deering K | American Academy of Neurology |
2011 | Days-out-of-role associated with insomnia and comorbid conditions in the America Insomnia Survey | Hajak G, Petukhova M, Lakoma M, Coulouvrat C, Roth T, Sampson N, Shahly V, Shillington A, Stephenson J, Walsh J, Kessler RC | Biol Psychiatry |
2011 | Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders, Second Edition criteria: results from the America Insomnia Survey | Roth T, Coulouvrat C, Hajak G, Lakoma MD, Sampson NA, Shahly V, Shillington AC, Stephenson JJ, Walsh JK, Kessler RC | Biol Psychiatry |
2011 | Creation of a Web-Based Multiple Sclerosis Patient-Reported Outcomes Research Program | Deering K, Agarwal S, Rajagopalan K, Harshaw Q, Shillington A, and the My MS Health Steering Committee | Value in Health |
2010 | Impact of Worsening Renal Function During Hospital Admission on Resource Utilization in Patients With Heart Failure | Herout P, Harshaw Q, Phatak H, Saka G, McNeill A, Wu D, Sazonov V, DeSagun R, Shirani J | Am J Cardiol |
2010 | Structure and Diagnosis of Adult Attention-Deficit/Hyperactivity Disorder: Analysis of Expanded Symptom Criteria from the Adult ADHD Clinical Diagnostic Scale | Kessler RC, Green JG, Adler LA, Barkley RA, Chatterji S, Faraone SV, Finkelman M, Greenhill LL, Gruber MJ, Jewell M, Russo LJ, Sampson NA, Van Brunt DL | Arch Gen Psychiatry |
2010 | Concordance of computerized self-report measures of DSM-IV-Tr, mood and anxiety disorders compared to gold standard clinical assessments in primary care | Kessker R, Farley A, Jewell M | ISPOR 15th Annual International Meeting |
2010 | Concordance of self-report measures of DSM-IV-TR, ICD-10, and RDC insomnia with standardized clinical assessments in the American Insomnia Survey (AIS) | Kessler R, Hajak G, Lakoma M | ISPOR 15th Annual International Meeting |
2010 | The American Insomnia Survey: an epidemiology study of insomnia prevalence and burden in a representative population | Kessler R, Coulouvrat C, Hajak G | ISPOR 15th Annual International Meeting |
2010 | Consensus and Discordance in the Management of Growth Hormone-Treated Patients: Results of a Knowledge, Attitudes, Beliefs, and Practices Survey | Miller BS, Shulman DI, Shillington A | Int J Pediatr Endocrinol |
2010 | The National Breakthrough Pain Survey (NBTPS): Design, Methodology, and Interim Results | Narayana A, Katz N, Shillington A | International Association for the Study of Pain 13th World Congress on Pain |
2010 | Dialysis health outcomes associated with pre-dialysis use of paricalcitol compared with no vitamin D receptor (VDR) activator treatment | Marx S, Frye C, Khan S | National Kidney Foundation |
2010 | Paricalcitol treatment in CKD patients with secondary hyperparathyroidism is associated with better health outcomes when compared with no vitamin D receptor [VDR] activator treatment | Sterz R, Frye C, Harshaw Q | National Kidney Foundation |
2010 | Comparative Effectiveness of Paricalcitol Versus Calcitriol Treatment in Chronic Kidney Disease [CKD] Patients with Secondary Hyperparathyroidism [SHPT] | Marx S, Frye C, Khan S, Harshaw Q, Audhya P, Deering K, Sterz R | National Kidney Foundation Spring Clinical Meeting Poster Presentation |
2010 | Reliability and Validity of the Brief Insomnia Questionnaire (BIQ) in the America Insomnia Survey (AIS) | Kessler R, Coulouvrat C, Hajak G, Lakoma MD, Roth T, Sampson N, Shahly V, Shillington A, Stephenson JJ, Walsh J, Zammit GK | Sleep |
2010 | Improved Resource Utilization Outcomes Associated with Predialysis Use of Paricalcitol for Secondary Hyperparathyroidism (SHPT) | Marx S, Frye C, Khan S, Harshaw Q, Audhya P, Deering K, Sterz R | Value in Health |
2009 | The American Insomnia Survey: an epidemiology study of insomnia in subjects with various comorbidities and/or conditions | Kessler RC, Coulouvrat C, Hajak G, Roth T, Sampson N, Shillington AC, Stephenson JJ, Walsh J | 3rd International Congress on Sleep Medicine of the World Association of Sleep Medicine and the 12th Brazilian Congress on Sleep Medicine |
2009 | All-Cause and Cardiovascular-Related Healthcare Resource Utilization and Costs Associated with Paricalcitol Use in Pre-Dialysis Chronic Kidney Disease (CKD) Patients with Secondary Hyperparathyroidism (SHPT) Compared with No Vitamin D Receptor Activator (VDRA) Therapy | Marx SE, Frye CB, Andress DL, Harshaw Q, Sterz R, Deering K, Audhya P | American Society of Nephrology's Renal Week |
2009 | Evaluation of Pre-Dialysis Doxercalciferol Use on Health Outcomes and Costs Compared to No Vitamin D Receptor Activator (VDRA) Treatment for Secondary Hyperparathyroidism (SHPT) | Harshaw Q, Andress DL, Marx SE, Frye CB, Sterz R, Deering K, Audhya P | American Society of Nephrology's Renal Week |
2009 | Impact of Pre-Dialysis Use of Calcitriol on Healthcare Resources Utilization and Costs Compared with No Vitamin D Receptor Activator (VDRA) Treatment for Secondary Hyperparathyroidism (SHPT) | Frye CB, Andress DL, Marx SE, Harshaw Q, Sterz R, Deering K, Audhya P | American Society of Nephrology's Renal Week |
2009 | Poorly Controlled Asthma and Health Service Utilization in New York in a Medicaid Managed Care Population | Silverman R, Reibman J, and the New York State Asthma Control and Co-morbidities Working Group | American Thoracic Society |
2009 | Discrepancies Between Knowledge, Attitudes and Beliefs and the Actual Practice (KABP) of Physicians who Care for Patients with Depression and/or Bipolar Disorder | Jewell M, Keck P, Golden WE, Brewster C, Farley AP, Harshaw Q | ISPOR 14th Annual International Meetin |
2009 | A Conceptual Analysis of the Costs of Care for a ?Major Bleed? in Studies of Antiplatelet and Antithrombotic Therapies | Harshaw Q, Frye CB, Hauch O | ISPOR 14th Annual International Meeting |
2009 | Improving data entry for post-marketing surveillance rhGH databases: Lessons from a knowledge (K), attitudes (A), beliefs (B) and practices (P) survey of Pediatric Endocrinologists | Kennedy J, Shulman D, Shillington A, Harshaw Q, Colgan K, Schwartz D, Kappy M, Wyatt D, Miller BS, Wilson D, McCormack L, Bakker B, Lippe B | Pediatric Endocrinology Nursing Society |
2009 | Comparing Outcomes Associated With Dose Manipulations of Enteric-Coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Renal Transplant Recipients? | Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS | Transplantation |
2008 | Switching HIV-infected, suppressed patients from ABC/3TC to FTC/TDF improves lipids - the SETTLE study | Gathe JC | 10th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV |
2008 | The STAndards for BipoLar Excellence (STABLE) Project: A bipolar disease quality improvement initiative to develop and validate evidence-based performance measures for national endorsement | Jewell MA, Golden W, Keck P | 13th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research |
2008 | Single Agent Therapy with Lopinavir/Ritonavir Suppresses HIV-1 Viral Replication in ARV Na?ve Patients: IMANI II ? 96 Week Final Results | Gathe JC, Yeh RF, Mayberry C, Nemecek J, Miguel B, Lipman BA, Fath MJ | 48th Annual ICAAC / IDSA 46th Annual Meeting |
2008 | Pharmacoeconomic analysis of bleeding complications and reoperation costs in patients with ACS receiving clopidogrel who require CABG surgery | Harshaw Q, Wygant GD, Hauch O, Berger JS, Frye CB, Becker RC | AHA 9th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke |
2008 | Impact of thienopyridines on bleeding complications with ACS patients requiring CABG surgery | Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC | American Heart Association Scientific Sessions |
2008 | Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis | Berger JS, Frye CB, Harshaw Q, Edwards FH, Steinhubl SR, Becker RC | J Am Coll Cardiol |
2008 | Psychosocial Interventions as Adjunctive Therapy for Bipolar Disorder | Sachs GS | J Psychiatr Prac |
2008 | Collaborative Mental Health and Primary Care for Bipolar Disorder | Williams JW, Manning JS | J Psychiatr Pract |
2008 | Clinical and Economic Effects of Unrecognized or Inadequately Treated Bipolar Disorder | Keck PE, Kessler RC, Ross R | J Psychiatr Pract |
2008 | Development of Evidence-Based Performance Measures for Bipolar Disorder: Overview of Methodology | Golden WE, Hermann RC, Jewell M, Brewster C | J Psychiatr Pract |
2008 | The STABLE Project: Addressing the Gap Between Evidence and Practice for Bipolar Disorder | Golden WE, Keck PE, Sachs GS, Oldham JM, Brewster C, Ross R | J Psychiatr Pract |
2008 | The Recovery Concept: Clinician and Consumer Perspectives | Stotland NL, Mattson MG, Bergeson S | J Psychiatr Pract |
2008 | Overview of the STAndards for BipoLar Excellence (STABLE) Project | Brewster C | J Psychiatr Pract |
2008 | Quality Improvement in Psychiatry: Why Measures Matter | Oldham JM, Golden WE, Rosof BM | J Psychiatr Pract |
2008 | Consensus and discordance in treating recombinant human growth hormone (rhGH) treated patients: results of a knowledge (K), attitudes (A), beliefs (B) and practices (P) [KABP] survey | Miller BS, Shulman D, Shillington AC | Pediatric Academic Societies and Asian Society for Pediatric Research Joint Meeting |
2008 | Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting | Pickard AS, Becker RC, Schumock GT, Frye CB | Pharmacotherapy |
2007 | Single agent therapy with lopinavir/ritonavir controls HIV-1 replication in the central nervous system | Yeh RF, Letendre S, Novak IS | 14th Conference on Retroviruses and Opportunistic Infections |
2007 | A comparison of adverse events and quality of life before and after switching from Kaletra? Soft-gel to Kaletra? Tablets in an African American cohort | Rawlings MK, McGhee TA, Casey-Bailey S, Pasley M | 2007 American Conference for the Treatment of HIV |
2007 | Performance indicators for bipolar disorder: development and feasibility testing | Williams JW, Golden W, Keck PE, Jewel M, Brewster C | 30th Annual Meeting of the Society of General Internal Medicine |
2007 | Linear growth and BMI during growth hormone treatment of children with craniopharyngioma compared to other organic growth hormone deficiencies: The National Cooperative Growth Study experience | Lustig R, Meacham L, Frane J, Frye C, Bakker B | 46th Annual Meeting of the European Society for Paediatric Endocrinology |
2007 | Single-agent Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral Replication in HIV-1 Na?ve Subjects: IMANI-2 48-Week Results | Gathe JC, Yeh RF, Mayberry C | 4th IAS Conference |
2007 | Success of a Comprehensive school-based asthma intervention on clinical markers and resource utilization for inner-city children with asthma in Chicago: the Mobile CARE Foundation's asthma management program | Patel B, Sheridan P, Detjen P | Journal of Asthma |
2006 | Tolerability and therapy preference of lopinavir/ritonavir (Kaletra) Soft-gel capsules and tablets as single agent in a cohort of HIV positive adult patients (IMANI-2) | Gathe JC, Lipman BA, Mayberry C, Miguel B, Nemecek J | 8th International Congress on Drug Therapy in HIV Infection |
2005 | Outbreak of catheter-associated Klebsiella oxytoca and Enterobacter cloacae bloodstream infections in an oncology chemotherapy center | Watson JT, Jones RC, Siston AM, Fernandez JR, Martin K, Beck E, Sokalski S, Jensen BJ, Arduino MJ, Srinivasan A, Gerber SI | Archives of Internal Medicin |
2005 | Antithrombotic therapy practices in US hospitals in an era of practice guidelines | Tapson VF, Hyers TM, Waldo AL | Archives of Internal Medicine |
2005 | Retrospective cohort study of granisetron administration for PONV prophylaxis and treatment | Shillington AC, Farley PA, Varkey JA, Dempsey C, Murdakes C | Hospital Pharmacy |
2005 | Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs | Caprini JA, Tapson VF, Hyers TM | Journal of Vascular Surgery |
2005 | Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation | Waldo AL, Becker RC, Tapson VF, Colgan KJ | Journal of the American College of Cardiology |
2004 | Oral capecitabine plus radiation therapy administered neoadjuvantly in the management of rectal cancer | Sharif A, Ajlouni M, Wollner I | 86th Annual Meeting of the American Radium Society |
2004 | The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) Study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization | Porter JA, Raebel MA, Conner DA | Am J Manag Care |
2004 | Disparities in antithrombotic management | Caprini JA, Ballard DJ, Becker RC | American Heart Association 5th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke |
2004 | Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide | Dempsey CL, Coop AJ, Shillington AC, Farley PA, Eberhardt DR, O'Briant S | American Journal of Health-System Pharmacy |
2004 | Venous thromboembolism treatment: results of a national database | Caprini JA, Marchev D, Glase C | American Venous Forum |
2004 | The National Anticoagulation Benchmark and Outcomes Report (NABOR?): evidence of a significant difference between guidelines and actual practice | Tapson VF, Hyers TM, Becker RC, Waldo AL, Colgan KJ, Shillington AC | International Society for Pharmacoeconomics and Outcomes Research 9th Annual International Meeting |
2004 | A comparison of hepatitis C treatment and outcomes at academic, private and Veterans? Affairs treatment centers | Jensen DM, Cotler SJ, Lam H, Harb G, Shillington AC | Journal of Alimentary Pharmacology and Therapeutics |
2004 | Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy: case report | Rogers LR, Remer SE, Sheela Tejwani S | Neuro-oncology |
2003 | A multicenter drug utilization evaluation program for Timentin? | Billeter M, Levato J, Waldrep T, Dempsey CL, Farley PA | ASHP Midyear Meeting |
2003 | Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension | Rich S, Shillington AC, McLaughlin V | American Journal of Cardiology |
2003 | Management of community-acquired pneumonia in one hospital compared with a national benchmark database | Hampton N, Romie A, Clewell L, Hadzima S, Gerdes JM | Hospital Pharmacy |
2003 | Complete and sustained remission of refractory cervical cancer following a single cycle of capecitabine a case report | Hindenburg AA, Matthews L | International Journal of Gynecological Cancer |
2003 | Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets | Duckworth W, Marcelli M, Padden M | Journal of Managed Care Pharmacy |
2003 | Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine | Mortimer JE, Lauman MK, Tan B, Dempsey CL, Shillington AC, Hutchins KS | Journal of Oncology Pharmacy Practice |
2003 | 5-HT3 antiemetic use in breast cancer patients receiving cyclophosphamide: a multi-center practice evaluation | Coop AJ, Farley PA, Shillington AC, Dempsey CL, Colgan KC | MASCC/ISOO 15th International Symposium |
2003 | A descriptive practice evaluation of granisetron utilization in the management of postoperative nausea and vomiting | Shillington A, Dempsey C, Farley PA, Coop A, Eberhardt DR, Varkey JA | New York State Society of Anesthesia Annual Meeting |
2003 | Hormone-refractory prostate cancer responding to capecitabine ? | El-Rayes, BF ,Black CA, Ensley JF | Urology |
2002 | Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea co-administered with metformin to glyburide/metformin tablets | Duckworth W, Marcelli M, Roman F | Academy of Managed Care Pharmacy |
2002 | Prognosis of patients with primary pulmonary hypertension induced by fenfluramine diet pills | Rich S, Shillington A, McLaughlin VV | American Thoracic Society |
2002 | Survival in primary pulmonary hypertension: the impact of epoprostenol therapy | McLaughlin VV, Shillington A, Rich S | Circulation |
2002 | A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies | Vaishampayan UN, Ben-Josef E, Philip PA | Int J Radiation Oncology Biology Physics |
2002 | Granisetron vs dolasetron for acute nausea and vomiting in high and moderately-high emetogenic chemotherapy | Tan M, Xu R, Seth R | MASCC/ISOO 14th International Symposium |
2001 | Chronic fatigue syndrome (CFS): pharmacoeconomic analysis of Ampligen? intervention | Shillington AC, Hilley H, Carter WA, Strayer DR | AACSF Annual Meeting |
bottom of page